A warning letter and two alerts issued during July show FDA’s continuing crackdown on sterile practices at drug compounders, including inadequate sterility procedures, environmental monitoring and gowning (IPQ April 14, 2014). The warning letter was issued to Dallas-based Abrams Royal Pharmacy following an inspection in December. FDA also alerted healthcare professionals during July to avoid sterile drugs coming from two Texas-based operations – Unique Pharmaceuticals and Downing Labs (aka NuVision Pharmacy).
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]